Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sadamu Homma

Showing results (11-20 of 72) with videos related to

Pageof 8
Sort By:
Immunotherapy|July 20, 2010
Cancer immunotherapy by fusions of dendritic cells and tumor cellsShigeo Koido, Eiichi Hara, Sadamu Homma, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancerYusuke Okuma, Yukio Hosomi, Yoshiro Nakahara, et al.
The Journal of Clinical Investigation|May 5, 2004
Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccineToshio Iinuma, Sadamu Homma, Tetsuo Noda, et al.
Archivum Immunologiae Et Therapiae Experimentalis|January 26, 2008
Dendritic/tumor fusion cell-based vaccination against cancerShigeo Koido, Eiichi Hara, Sadamu Homma, et al.
International Immunopharmacology|November 4, 2017
Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cellsSadamu Homma, Kazumi Hayashi, Kosaku Yoshida, et al.
Plos One|December 1, 2017
Encryption of agonistic motifs for TLR4 into artificial antigens augmented the maturation of antigen-presenting cellsMasaki Ito, Kazumi Hayashi, Tamiko Minamisawa, et al.
Journal of Gastroenterology|November 14, 2003
Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinomaSadamu Homma, Kazuo Matai, Masaki Irie, et al.
Cancer Science|February 28, 2016
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulationKazumi Hayashi, Eijiro Nagasaki, Shin Kan, et al.
Plos One|October 25, 2014
Combinatorial contextualization of peptidic epitopes for enhanced cellular immunityMasaki Ito, Kazumi Hayashi, Eru Adachi, et al.
Cancer Immunology, Immunotherapy : CII|January 16, 2007
Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparationSadamu Homma, Yukiko Sagawa, Hideo Komita, et al.
Pageof 8

Showing results (11-20 of 72) with videos related to

Sort By:
Pageof 8
Immunotherapy|July 20, 2010
Cancer immunotherapy by fusions of dendritic cells and tumor cellsShigeo Koido, Eiichi Hara, Sadamu Homma, et al.
Lung Cancer (Amsterdam, Netherlands)|February 19, 2017
High plasma levels of soluble programmed cell death ligand 1 are prognostic for reduced survival in advanced lung cancerYusuke Okuma, Yukio Hosomi, Yoshiro Nakahara, et al.
The Journal of Clinical Investigation|May 5, 2004
Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccineToshio Iinuma, Sadamu Homma, Tetsuo Noda, et al.
Archivum Immunologiae Et Therapiae Experimentalis|January 26, 2008
Dendritic/tumor fusion cell-based vaccination against cancerShigeo Koido, Eiichi Hara, Sadamu Homma, et al.
International Immunopharmacology|November 4, 2017
Nafamostat mesilate, a serine protease inhibitor, suppresses interferon-gamma-induced up-regulation of programmed cell death ligand 1 in human cancer cellsSadamu Homma, Kazumi Hayashi, Kosaku Yoshida, et al.
Plos One|December 1, 2017
Encryption of agonistic motifs for TLR4 into artificial antigens augmented the maturation of antigen-presenting cellsMasaki Ito, Kazumi Hayashi, Tamiko Minamisawa, et al.
Journal of Gastroenterology|November 14, 2003
Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinomaSadamu Homma, Kazuo Matai, Masaki Irie, et al.
Cancer Science|February 28, 2016
Gemcitabine enhances rituximab-mediated complement-dependent cytotoxicity to B cell lymphoma by CD20 upregulationKazumi Hayashi, Eijiro Nagasaki, Shin Kan, et al.
Plos One|October 25, 2014
Combinatorial contextualization of peptidic epitopes for enhanced cellular immunityMasaki Ito, Kazumi Hayashi, Eru Adachi, et al.
Cancer Immunology, Immunotherapy : CII|January 16, 2007
Mechanism of antitumor effect on mouse hepatocellular carcinoma by intratumoral injection of OK-432, a streptococcal preparationSadamu Homma, Yukiko Sagawa, Hideo Komita, et al.
Pageof 8